What the Data Actually Shows
In the largest PCR-tested explant capsule series ever published, Dr. Whitfield's research team analyzed over 600 consecutive samples of explant capsule tissue using next-generation sequencing — the same technology used in advanced pathogen detection.
PCR-based analysis identifies microbial contamination missed by standard culture methods.
of tested capsules contained bacterial contamination
Standard culture methods — the conventional approach used in most surgical practices — miss this contamination entirely. PCR testing (polymerase chain reaction) detects bacterial DNA at concentrations too low for traditional cultures, revealing chronic sub-clinical infections that drive ongoing inflammation.
Dominant Organisms Identified
Cutibacterium acnes and Staphylococcus epidermidis were the most frequently identified organisms — common skin flora that form biofilms on implant surfaces. These biofilms produce antagonistic compounds that drive chronic inflammation and immune responses.
Published Study
Whitfield R, Tipton CD, Diaz N, Ancira J, Landry KS. "Clinical Evaluation of Microbial Communities and Associated Biofilms with Breast Augmentation Failure." Microorganisms. 2024;12(9):1830.
View on PubMed
Why Dr. Whitfield
Dr. Robert Whitfield is a board-certified plastic surgeon whose career spans nearly three decades of surgical practice, peer-reviewed research, and institutional leadership. His work on breast implant illness is grounded in evidence he has helped generate — not opinion.
American Board of Plastic Surgery
The only board recognized by ABMS for the full scope of plastic surgery
Fellow, American College of Surgeons (FACS)
Awarded for demonstrated competence, ethical fitness, and commitment to surgical excellence
ASERF Past President (2019–2020) & BII Task Force Vice Chair
As ASERF Past President, committed to funding research on breast implant illness and advancing evidence-based understanding at the FDA
FDA Hearing Witness — March 2019
Testified before the FDA panel that led to the black box warning on all breast implants
15 Peer-Reviewed Publications
Research spanning plastic surgery, microsurgery, oncology, and biofilm analysis
Precision Explant Surgery
Dr. Whitfield's surgical approach is built on a fundamental principle: the goal is not just to remove the implant — it's to remove the entire source of inflammation, identify what's actually present in the tissue, and give the body the best possible conditions for recovery.
En Bloc Capsulectomy
The implant and its surrounding capsule are removed as a single, intact unit — without opening the capsule or exposing the surgical field to its contents. This technique is considered the gold standard for patients with suspected contamination or biofilm formation, as it minimizes the risk of dispersing inflammatory material into surrounding tissue.
Total Capsulectomy
When en bloc removal is not anatomically feasible — due to capsule adhesion to the chest wall or rib cage — Dr. Whitfield performs a total capsulectomy, removing all capsule tissue through meticulous dissection. The goal remains the same: complete removal of the capsule and any associated biofilm, with PCR testing of the removed tissue to identify contamination.
PCR Tissue Testing
Every capsule removed in Dr. Whitfield's practice is sent for PCR-based analysis — the same next-generation sequencing technology used in advanced pathogen detection. This identifies bacterial and fungal DNA at concentrations too low for standard culture methods, giving patients definitive answers about what was present in their tissue.
Genetic & Toxic Burden Assessment
Beyond the surgical procedure, Dr. Whitfield's practice incorporates advanced diagnostic testing including genetic predisposition analysis and toxic burden assessment. These evaluations help identify individual susceptibility factors — such as detoxification pathway variants — that may influence both symptom severity and recovery trajectory.
SHARP Surgery Center — Dr. Whitfield's dedicated surgical facility, launching 2026.
Testimony Before the FDA
On March 25–26, 2019, Dr. Whitfield testified before the FDA's General and Plastic Surgery Devices Panel as ASERF Past President (2019–2020) and Vice Chair of the Breast Implant Illness Task Force.
At a time when breast implant illness was still widely dismissed by the medical establishment, he presented funded research initiatives and argued that evidence-based investigation — not dismissal — was the appropriate response.
"In that capacity, I am working to identify evidence-based research to better understand breast implant illness and breast implant-associated ALCL. This research will then be used to educate the surgeons and benefit the patients associated."
— Dr. Robert Whitfield, FDA Hearing Transcript, p. 449, March 26, 2019
Regulatory Outcomes
The March 2019 hearing was a turning point in federal breast implant regulation. The testimony heard over those two days directly informed a series of FDA actions that fundamentally changed how breast implants are regulated, labeled, and communicated to patients.
New Labeling Recommendations
Updated requirements for structured patient decision checklists and clearer risk communication.
Allergan Textured Implant Recall
FDA requested recall of BIOCELL textured implants — the first such action in device history.
Black Box Warning Mandated
The strictest labeling available — now required on all breast implants, warning of BIA-ALCL and systemic symptoms.
Mandatory Informed Consent
Surgeons must now provide standardized decision checklists before breast implant surgery.
Learn More About Breast Implant Illness
In-depth educational articles from Dr. Whitfield's practice — written for patients who want to understand the science, not just the summary.
Educational Resources
Whether you're researching breast implant illness for the first time or preparing for a consultation, these resources provide a data-driven foundation for understanding your options.
Understanding Breast Implant Illness
Inflammation Support Guide
A practical guide to understanding and managing inflammation — the underlying driver of most BII symptoms. Covers dietary strategies, lifestyle modifications, and evidence-based supplementation.
BII Mini Course
Dr. Whitfield's focused introduction to breast implant illness — what it is, how it's diagnosed, what the research shows, and what your options are. Designed for patients at the beginning of their BII journey.
Breast Implants, Explant Surgery & BII
Dr. Whitfield's comprehensive guide to breast implant illness, explant surgery, and recovery — written for patients who want to understand the science and make informed decisions.
The SHARP Method
SHARP Mini Course
A condensed introduction to the SHARP Method — biological preparation, surgical expectations, and structured recovery — directly from Dr. Whitfield.
The SHARP Method Book
The complete guide to Dr. Whitfield's three-phase protocol: pre-surgical optimization, precision explant surgery, and engineered recovery.
References & Published Research
Whitfield R, Tipton CD, Diaz N, Ancira J, Landry KS. "Clinical Evaluation of Microbial Communities and Associated Biofilms with Breast Augmentation Failure." Microorganisms. 2024;12(9):1830.
PubMed: 39338504FDA General and Plastic Surgery Devices Panel Meeting. March 25–26, 2019. Docket No. FDA-2019-N-0426.
Official TranscriptFDA Breast Implant Postapproval Studies. Boxed Warning and Updated Labeling for Breast Implants. October 2021.
FDA Breast Implant SafetyWhitfield RM, Rios LM Jr, DiBernardo BE. "Making Fat Transfer to Buttocks Safer." Aesthet Surg J. 2017;37(10):1199-1200.
PubMed: 29044365McMains CC, Mather TL, Adamson KA, Whitfield R, et al. "Heparin-induced thrombocytopenia in lower extremity free tissue transfers." Microsurgery. 2023.
PubMed: 37339917